Biogen Names Priya Singhal as Executive Vice President, Head of Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Biogen (BIIB) gains ahead of lecanemab PDUFA
January 6, 2023 7:05 AM ESTBiogen (NASDAQ: BIIB) is gaining 1% in pre-open trade ahead of lecanemab's accelerated approval PDUFA today.
After the close, analysts at RBC Capital noted that Eisai's patient assistance hotline for Leqembi/lecanemab just became active suggesting "increased likelihood an approval."
... MoreRBC Capital on Biogen (BIIB): 'a very favorable stock setup'
January 5, 2023 4:11 PM ESTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Sometime between late this morning and now, Eisai's patient assistance hotline for Leqembi/lecanemab just became active, whereas for the last several weeks the phone number (which we obtained via Google search) had not been... More
Biogen's (BIIB) accelerated PDUFA lecanemab approval the likely outcome claim analysts
January 5, 2023 11:50 AM ESTBiogen's (NASDAQ: BIIB) lecanemab's accelerated approval PDUFA is slated for Friday, January 6, and analysts have been weighing in with their view heading into the date.
Jefferies analyst Michael Yee, who has a Buy rating and a $350 price target on Biogen shares, said in a note to clients that the "consensus assumes clean approval, which is reasonable though mostly... More
